Cellular housekeeping just became significantly more precise. The ability to selectively eliminate disease-causing proteins represents one of medicine's most promising frontiers, offering potential treatments for cancers, neurodegeneration, and metabolic disorders that were previously considered undruggable. This breakthrough addresses a fundamental limitation in developing molecular glue degraders—compounds that act as matchmakers between target proteins and the cellular machinery responsible for protein disposal.
Researchers engineered ZZ1, a molecular glue degrader that operates through an elegant two-step mechanism. Initially inactive as a prodrug, ZZ1 transforms within cells to expose a sulfinic acid group—a negatively charged molecular handle. This activated form binds to YPEL5, a component of the CTLH ubiquitin ligase complex, through complementary electrostatic interactions. The binding event recruits BET-family proteins for degradation, effectively removing these cancer-associated targets from cells.
This represents a paradigm shift from current molecular glue strategies, which rely primarily on hydrophobic interactions and serendipitous binding events. The charged glue approach enables rational design targeting the estimated 20% of human proteins containing acidic or basic surface regions—previously inaccessible degrons. The work also reveals YPEL5's previously unknown role as a substrate recruitment factor, expanding our understanding of cellular quality control mechanisms. While demonstrated specifically for BET proteins, the underlying chemistry suggests broad applicability across protein families, potentially unlocking therapeutic targets that have resisted conventional small molecule approaches. The prodrug strategy adds an additional layer of selectivity, activating only in appropriate cellular contexts.